{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:06:48Z","timestamp":1783487208660,"version":"3.55.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"DOI":"10.1210\/jc.2012-4137","type":"journal-article","created":{"date-parts":[[2013,4,27]],"date-time":"2013-04-27T04:31:05Z","timestamp":1367037065000},"page":"2693-2700","source":"Crossref","is-referenced-by-count":56,"title":["Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up"],"prefix":"10.1210","volume":"98","author":[{"given":"Eleonora","family":"Molinaro","sequence":"first","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Giani","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Agate","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Biagini","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Pieruzzi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Brozzi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viola","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Piaggi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vitti","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Pacini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (F.P.), Section of Endocrinology and Metabolism, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine (E.M., C.G., L.A., L.P., F.Bi., F.Br., C.C., A.B., D.V., P.P., P.V., R.E.), World Health Organization Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56100 Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113294217900_B1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113294217900_B2","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1210\/jc.2003-031167","article-title":"A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer","volume":"89","author":"Sawka","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","article-title":"Current approaches to primary therapy for papillary and follicular thyroid cancer","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1530\/eje.0.1500105","article-title":"Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective","volume":"150","author":"Schlumberger","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113294217900_B5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1210\/jc.2005-1651","article-title":"Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study","volume":"91","author":"Pacini","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B6","first-page":"1482","article-title":"A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation","volume":"43","author":"Robbins","year":"2002","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113294217900_B7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/105072501316973127","article-title":"Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin","volume":"11","author":"Robbins","year":"2001","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113294217900_B8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00006231-200608000-00005","article-title":"Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants","volume":"27","author":"Barbaro","year":"2006","journal-title":"Nucl Med Commun"},{"key":"key\n\t\t\t\t2019041113294217900_B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-6614-3-9","article-title":"Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi","volume":"3","author":"Kukulska","year":"2010","journal-title":"Thyroid Res"},{"key":"key\n\t\t\t\t2019041113294217900_B10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/jc.2006-1345","article-title":"131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review","volume":"92","author":"Hackshaw","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B11","doi-asserted-by":"crossref","first-page":"v214","DOI":"10.1093\/annonc\/mdq190","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Pacini","year":"2010","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041113294217900_B12","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1210\/jc.2007-0225","article-title":"A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer","volume":"92","author":"Pilli","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/COC.0b013e318201a41a","article-title":"Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients","volume":"35","author":"Rosario","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113294217900_B14","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.2967\/jnumed.108.050591","article-title":"Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity","volume":"49","author":"Ros\u00e1rio","year":"2008","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113294217900_B15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","article-title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer","volume":"366","author":"Schlumberger","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113294217900_B16","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","article-title":"Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer","volume":"366","author":"Mallick","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113294217900_B17","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1210\/jc.2009-0869","article-title":"Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal","volume":"94","author":"Elisei","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2967\/jnumed.107.049072","article-title":"Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal","volume":"49","author":"Tuttle","year":"2008","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113294217900_B19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/thy.2011.0242","article-title":"Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine","volume":"22","author":"Rosario","year":"2012","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113294217900_B20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-6614-4-9","article-title":"Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and\/or radioiodine in the Boston, MA area: a retrospective chart review","volume":"4","author":"Leung","year":"2011","journal-title":"Thyroid Res"},{"key":"key\n\t\t\t\t2019041113294217900_B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0025-6196(12)61179-3","article-title":"Treating differentiated thyroid carcinoma: where do we draw the line?","volume":"66","author":"Mazzaferri","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041113294217900_B22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/thy.1997.7.265","article-title":"Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma","volume":"7","author":"Mazzaferri","year":"1997","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113294217900_B23","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1210\/jc.2001-011918","article-title":"Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal","volume":"87","author":"Pacini","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/jcem-71-2-414","article-title":"Natural history, treatment, and course of papillary thyroid carcinoma","volume":"71","author":"DeGroot","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer","year":"2009","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113294217900_B26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/eje.1.02158","article-title":"European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium","volume":"154","author":"Pacini","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113294217900_B27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t2019041113294217900_B28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041113294217900_B29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hed.10277","article-title":"Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy","volume":"25","author":"Wiseman","year":"2003","journal-title":"Head Neck"},{"key":"key\n\t\t\t\t2019041113294217900_B30","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019041113294217900_B31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hed.21520","article-title":"Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer","volume":"33","author":"Almeida","year":"2011","journal-title":"Head Neck"},{"issue":"5","key":"key\n\t\t\t\t2019041113294217900_B32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/thy.2012.0050","article-title":"Salivary and lacrimal gland dysfunction after remnant ablation with radioiodine in patients with differentiated thyroid carcinoma prepared with recombinant human TSH","volume":"23","author":"Rosario","year":"2013","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113294217900_B33","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2004-1771","article-title":"Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma","volume":"90","author":"Kim","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113294217900_B34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF03346558","article-title":"Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer","volume":"33","author":"Piccardo","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113294217900_B35","first-page":"988","article-title":"Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer","volume":"45","author":"Toubeau","year":"2004","journal-title":"J Nucl Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/7\/2693\/9046416\/jcem2693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T22:18:46Z","timestamp":1595715526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/7\/2693\/2536933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-4137","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}